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Abstract. Cox SN, Pesce F, El-Sayed Moustafa JS,
Sallustio F, Serino G, Kkoufou C, Giampetruzzi A,
Ancona N, Falchi M, Schena FP (University of Bari
Aldo Moro; University of Bari, Bari, Italy; Imperial
College London; King’s College London, London,
UK; Laboratory of Experimental Immunopathology;
University of Bari Aldo Moro; and ISSIA, CNR, Bari,
Italy). Multiple rare genetic variants co-segregating
with familial IgA nephropathy all act within a single
immune-related network. J Intern Med 2016; doi:
10.1111/joim.12565.
Background. IgA nephropathy (IgAN) is a common
complex disease with a strong genetic involvement.
We aimed to identify novel, rare, highly penetrant
risk variants combining family-based linkage anal-
ysis with whole-exome sequencing (WES).
Methods. Linkage analysis of 16 kindreds of South
Italian ancestry was performed using an ‘affected-
only’ strategy. Eight most informative trios com-
posed of two familial cases and an intrafamilial
control were selected for WES. High-priority vari-
ants in linked regions were identified and validated
using Sanger sequencing. Custom TaqMan assays
were designed and carried out in the 16 kindreds
and an independent cohort of 240 IgAN patients
and 113 control subjects.
Results. We found suggestive linkage signals in 12
loci. After sequential filtering and validation of
WES data, we identified 24 private or extremely
rare (MAF <0.0003) linked variants segregating
with IgAN status. These were present within
coding or regulatory regions of 23 genes that
merged into a common functional network. The
genes were interconnected by AKT, CTNNB1,
NFKB, MYC and UBC, key modulators of WNT/
b-catenin and PI3K/Akt pathways, which are
implicated in IgAN pathogenesis. Overlaying
publicly available expression data, genes/pro-
teins with expression notably altered in IgAN
were included in this immune-related network. In
particular, the network included the glucocorti-
coid receptor gene, NR3C1, which is the target of
corticosteroid therapy routinely used in the
treatment of IgAN.
Conclusion. Our findings suggest that disease
susceptibility could be influenced by multiple
rare variants acting in a common network that
could provide the starting point for the identifi-
cation of potential drug targets for personalized
therapy.
Keywords: familymedicine,genepolymorphism,genet-
ics, glomerulonephritis, kidney disease.
Introduction
Immunoglobulin A nephropathy (IgAN) is the most
common form of primary glomerulonephritis
worldwide amongst patients undergoing renal
biopsy [1, 2]. The gold standard for diagnosis
depends entirely on this invasive procedure. The
genetic component of IgAN, supported by familial
clustering, may influence the disease on various
levels and may also contribute to the variation
observed in prevalence [3]. The phenotypic vari-
ability of IgAN, characterized by recurrent episodes
of gross haematuria concomitant with upper res-
piratory tract infections or persistent microscopic
haematuria and/or mild proteinuria, suggests that
*These authors contributed equally.
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this glomerulonephritis is a complex disease in
which multiple genes may be involved and the
kidneys are simple bystanders [2].
Various genomewide genetic approaches have been
used to study IgAN with the aim to identify specific
markers involved in its susceptibility. Genome-
wide association studies (GWASs) testing common
variants with relatively small effects [4] have led to
the identification of various susceptibility loci [5–
9]. Furthermore, these studies have provided
insights into the complex genetic architecture of
IgAN and attempted to explain how susceptibility
loci correlate with differences in disease prevalence
amongst world populations [8, 10]. Most of the
identified loci have been rigorously replicated sug-
gesting a strong genetic component, but still a large
proportion of disease risk remains unexplained
and there are likely to be additional loci that have
not been discovered [11].
On the other hand, genomewide linkage analyses
(GWLAs), evaluating the co-segregation of genetic
markers with the disease in multiplex families,
have identified several linked chromosomal regions
including 2q36, 4q26–31, 6q22–23 and 17q12–22
[12–14]. These loci are distinct from those identi-
fied by GWASs and ultimately both approaches
have been unable to identify the exact casual genes
involved in IgAN susceptibility [15].
Rare variants, which are not interrogated by
GWASs, could be responsible for a substantial
proportion of complex human diseases [16] and
may explain a considerable portion of their missing
heritability [4]. This concept has been recently
demonstrated in an innovatively designed study of
age-related macular degeneration in which rare
causative coding variants were pinpointed within
known associated genetic loci [17]. Because 85% of
the disease-causing mutations are likely to be
located in well-annotated coding regions of the
genome [18], the cost-effective whole-exome
sequencing (WES) strategy is a useful approach in
the identification of rare causative variants.
Here, we report the first study of IgAN employing a
combined multistep approach for the identification
of rare variants associated with this disease. Using
the family-based GWLA approach, we first identi-
fied genomic regions containing potential suscep-
tibility loci. Then, WES of selected IgAN familial
cases and controls was used to fine map the linked
regions and identify rare segregating functional
genomic variants potentially involved in the patho-
genesis of familial IgAN.
Materials and methods
Sample donors
The genomewide linkage analysis involved 34
biopsy-proven familial IgAN patients and 112 rel-
atives from 16 Italian kindreds of South Italian
ancestry (Table 1 and Figure S1). Recruitment
strategies are available on the European IgAN
Consortium website (www.igan.net) [19]. Briefly,
familial IgAN was diagnosed when at least two
family members had biopsy-proven IgAN; the
remaining family members underwent urinalysis.
Unaffected family members had at least three
documented normal urinalyses (Figure S1). An
independent cohort of 240 biopsy-proven IgAN
patients and 113 healthy blood donors (HBDs)
were included in the study for custom TaqMan SNP
genotyping assays. Written informed consent was
obtained from all study participants. The study
was carried out according to the principles of the
Declaration of Helsinki and was approved by the
Policlinico di Bari Ethics Review Board.
GWLAs of IgAN families
Microarray genotyping is available under the GEO
accession number GSE44974 (http://
www.ncbi.nlm.nih.gov/geo/) [20], and a detailed
description can be found in the Supplementary
Methods. Individuals with more than 5% missing
genotypes and more than 5% Mendelian errors
were excluded. Markers that failed the Hardy–
Weinberg equilibrium test (P ≤ 1 9 106) and those
with a minor allele frequency (MAF) of ≤0.05 were
excluded. Genotyping errors were also detected
and removed using Merlin error detection analysis
(–error option). Nonparametric linkage (modelling
linkage disequilibrium with r2 > 0.10) analysis was
performed on 146 individuals for a total of 16
families and 227 114 SNPs.
The Whittemore and Halpern NPL all statistics [21]
was used to test for allele sharing amongst affected
individuals, calculating the LOD score using the
Kong and Cox linear model (–npl option) [22]. A P-
value <5.0 9 103 (LOD >1.5) [23] was deemed
significant. The study was powered to detect a
maximum possible LOD score of 5.052
(P = 7.05 9 107) for this data set. The analyses
were carried out using Merlin software (version
1.1.2) [24].
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WES of IgAN families
We performed WES on 16 most informative IgAN
patients belonging to eight nonconsanguineous
families and eight intrafamilial controls. For the
selection of the internal (intrafamilial) negative
controls, we performed an identical by descent
(IBD) analysis on each of these eight families and
identified the closest relative (for each affected
individual) with the least IBD sharing (genetically
discordant) in the region of interest [24, 25]. Exome
libraries were prepared using 3 lg of genomic DNA.
Sequence reads were mapped to the reference
human genome (UCSC Genome Browser hg19)
using the Burrows–Wheeler aligner (BWA; version
0.5.9-r16) [26], with default parameters. The Best
Practices Workflow of Genome Analysis Toolkit
(GATK, http://www.broadinstitute.org) [27] was
used for improving the alignments and for geno-
type calling with recommended parameters. Geno-
types were called at first with the GATK Unified
Genotyper (UG, version 2.7-4), and the GATK
VariantRecalibrator tool was used to score variant
calls by a machine-learning algorithm and to
identify a set of high-quality variants using the
variant quality score recalibration (VQSR) proce-
dure. GATK was used to filter high-quality variants
with hard filtering criteria (variant confidence score
≥30, mapping quality ≥40, read depth ≥5 and
strand bias FS filter <60). At a later date, our
exome data were also reprocessed using the newer
GATK algorithm Haplotype Caller (HC, version
v3.3). To be conservative, we decided to retain
and evaluate both variant lists generated by HC
and UG. These two tools are based on different
algorithms [28], but both evaluate haplotypes
using an affine gap penalty pair hidden Markov
model [29]. Variants were then annotated with the
software snpEFF (snpEff_v2_0_5, http://snpeff.-
sourceforge.net/download.html) [30] and catego-
rized into four classes (high, moderate, low and
modifier), and the functional impact of coding
variants was also predicted. Low-impact variants
were predicted by snpEFF and filtered out as they
were synonymous coding and ‘assumed to be
mostly harmless or unlikely to change protein
behaviour’ as described in the manual (http://
snpeff.sourceforge.net/SnpEff_manual.html).
Table 1 Clinical and demographic features of IgAN patients, relatives and HBD included in the studya
IgANb Relativesb IgANc HBDc
Number 34 112 240 113
Male/female 23/11 46/66 164/76 84/29
Age of onset (years) 25  11 n.d 27  11 n.d
sCr (mg/dL) 1.36  0.98 n.d 1.18  0.59 0.87  0.01
eGFR(mL min1 per 1.73 m2) 88.3  18 n.d 88  29 n.d
CKD stage 1 (%) 55 n.d 53 n.d
CKD stage 2 (%) 24 n.d 29 n.d
CKD stage 3 (%) 15 n.d 12 n.d
CKD stage 4 (%) 3 n.d 6 n.d
CKD stage 5 (%) 3 n.d 0 n.d
Proteinuria (g/24 h) 1.09  0.75 n.d 1.07  1.28 n.d
Hypertension (%) 37% n.d 36% n.d
Histological classification (%) G1 41%
G2 24%
G3 35%
n.d G1 38%
G2 41%
G3 20%
n.d
aValues are expressed as meanS.D. Abbreviations: sCr, serum creatinine; eGFR, estimated glomerular filtration rate
(eGFR) has been calculated using the CKD-EPI creatinine formula (mL min1 per 1.73 m2); G1, Grade 1 mild; G2, Grade 2
moderate; G3 Grade 3 severe; HBS, Healthy Blood Donors; n.d, not determined. Demographic, clinical and histological
data refer to the time of biopsy-proven diagnosis.
bThese patients and relatives have been included in the in the Microarray Genotyping cohort and in the exome-sequencing
study.
cThese patients and controls have been included TaqMan genotyping cohort.
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Sequence data were filtered against multiple data-
bases using annovar (http://annovar.openbioin-
formatics.org, version 2013Aug23), and MAFs of
the called variants were compared against dbSNP
137 (ftp://ftp.ncbi.nih.gov/snp/) and 1000 Gen-
omes Project, where we filtered against the Euro-
pean cohort (EUR.MAF, April 2002 release, ftp://
ftp.1000genomes.ebi.ac.uk/vol1/ftp). Then, vari-
ants were visualized with Integrative Genomics
Viewer (IGV, version 2.3.36). The concordance
between the genotypes of the variants identified
through WES and bead SNP genotyping was eval-
uated using the PLINK program. Concordance was
of 96% and 94% for UG and HC, respectively. A
more detailed description can be found in the
Supplementary Methods.
Validation study: Sanger sequencing and variant segregation analysis
Segregating variants in affected individuals were
prioritized based on their scaled C-scores from the
Combined Annotation Dependent Depletion
(CADD) webserver (http://cadd.gs.washing-
ton.edu) [31]. Priority variants were validated using
Sanger sequencing on IgAN patients and controls
from the WES group. Validated variants were
further tested in extended families to evaluate their
segregation in other pedigree members with uri-
nary abnormalities. See Supplementary Methods
for detailed information.
Frequency evaluation: database query and TaqMan SNP genotyping
The frequencies of variants validated by Sanger
sequencing were evaluated using the Exome Aggre-
gation Consortium (ExAC; http://exac.broadinsti-
tute.org) and the 1000 Genomes phase 3 (http://
browser.1000genomes.org) databases. Genotyping
was performed using TaqMan assays. Briefly,
appropriate amplification primers were designed
for the genomic region containing the variant of
interest. TaqMan reactions were carried out in
25 lL volumes containing 10 ng DNA, according to
the manufacturer’s protocols. Amplification
parameters were as follows: hot start at 95 °C for
10 min; 40 amplification cycles (95 °C for 15 s,
60 °C for 1 min). Results were obtained using a
StepOnePlus Real-Time PCR system and genotypes
were called using STEPONE Software v2.2 (Life
Technologies, Monza, Italy). Genotype clustering
patterns were examined and confirmed to be of
good quality. Assay controls with known genotype
from Sanger sequencing were included in each
plate.
Network analysis to identify rare family variants belonging to known
pathways
To assess biological relationships amongst genes,
we used Ingenuity Pathway Analysis (IPA) software
(Ingenuity Systems, Redwood City, CA, USA;
http://www.ingenuity.com). We performed canon-
ical pathway analysis. IPA generated networks
based on the connectivity of the genes and com-
puted a score for each network. These scores
indicated the likelihood of focus genes belonging
to a network versus those obtained by chance. A
score of 2 indicates a 1 in 100 chance that the
focus genes are together in a network because of
random chance. The canonical pathway analysis
identified the pathways from the IPA library of
canonical pathways that were most significant to
the input data set. Significance of the canonical
pathway was calculated using Fisher’s exact test.
The whole data set composed of the 52 in silico-
identified segregating variants was not evaluated
as it contained nonconfirmed variants or variants
that were also present in the intrafamilial control.
For network analysis, we uploaded 23 genes which
contained 24 co-segregating variants with the IgAN
status. IPA associates a list of drug targets with
generated networks based on knowledge base data
(US Food and Drug Administration, Goodman and
Gilman’s The Pharmacological Basis of Therapeu-
tics and Mosby’s Drug Consult). The upstream
regulator analysis has been used to identify a list of
transcriptional regulators that explains observed
gene expression changes in our data sets. The
calculated overlap P-value measures whether there
is a statistically significant overlap between the
dataset genes and the genes that are regulated by
the transcription regulator. It is calculated using
Fisher’s exact test and significance is generally
attributed to P-values <0.01.
Results
GWLA of IgAN families
Sixteen multiplex families comprising 34 IgAN
patients and 112 relatives were included in the
linkage study (Figure S1). Nonparametric linkage
‘affected-only’ analysis confirmed and refined the
evidence for linkage to previously described sus-
ceptibility loci for IgAN on chromosomes 4q24–28
(LOD 2.4, P = 4.5 9 104), 6q22–23 (LOD 1.6, P =
3.2 9 103) and 17q12–21 (LOD 1.6, P = 3.3 9
103) [12, 13]. Our previous linkage study was
performed using 400 microsatellites [13]; here, we
adopted a SNP-based strategy using a finer genetic
S. N. Cox et al. Rare genetic variants in IgA nephropathy
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map of 300 000 SNPs (see Supplementary material
for detailed description). We found nine additional
suggestive linked regions (LOD >1.5 or
P < 5.0 9 103) in other areas of the genome
(Table 2 and Figure S2). Interestingly, different
families shared multiple linkage signals spread
across 11 chromosomes. This prompted us to focus
the sequencing on eight of these families that were
providing the strongest contribution to multiple
linkage signals in novel and known regions (Fig-
ure S3).
WES of IgAN families
From each of the eight kindreds, we selected a trio
comprising two affected individuals and an inter-
nal negative control showing in the regions of
interest the least IBD sharing with the affected
individuals [24, 25]. This resulted in a total of 16
cases and eight familial controls to be sequenced
(Figure S3).
We performed a target capture procedure able to
target 62 Mb of the genome including the exome,
microRNA sites and noncoding upstream and
downstream regulatory regions. Parallel sequenc-
ing generated a mean of 3.6 billion bases of raw
data per sample (range: 0.745–5.9 Gb). After map-
ping, 98% of reads mapped to the human reference
genome with a mean coverage of 209. Two distinct
algorithms from the GATK were used to call vari-
ants: UG and HC (Table S1), identifying an average
of 42 975 and 31 390 variants per individual,
respectively.
The genetic variant annotation and the effect
prediction toolbox SnpEff [30] were used to anno-
tate variants based on their genomic locations, and
the coding effects were also predicted.
To identify susceptibility variants potentially
involved in IgAN, we adopted a filtering strategy,
illustrated in Fig. 1, based on (i) MAF (excluding
common variants with EUR.MAF >0.01), (ii) ‘low’
effect prediction (excluding all synonymous coding
SNPs) and (iii) quality of the variant based on
GATK’s Variant Call Quality Recalibration (VCQR).
This approach led to a total of 21 001 and 27 597
called variants for UG and HC, respectively (Fig. 1).
Some variants were called uniquely by one or the
other algorithm so we decided to retain both UG
and HC lists (Figure S4). Furthermore, we found
that the vast majority of variants in each gene
region were comparable between the two callers
(Figure S5). Linkage data were then incorporated
in the filtering pipeline and only variants located
within linked genomic intervals (i.e. showing a
LOD score >1.5 or P < 5 9 103) were considered
further (Table S2), leading to the identification of
3112 and 5654 variants for UG and HC, respec-
tively (Fig. 1a). Finally, priority was given to vari-
ants that co-segregated in affected individuals and
were absent in the intrafamilial control. This
procedure was adopted to exclude co-segregating
variations due to the relatedness of the trios, thus
highlighting the ones that were effectively involved
with IgAN. Each set of co-segregating variants per
family was then visually inspected using the
Integrated Genomics Viewer (Fig. 1b). Visual
inspection permitted assessment of the variants
in their genomic context, evaluation of repeat
sequences and ascertainment that the variation
was not an artefact. Furthermore, read pair
orientation and overall depth of sequencing in
cases and controls were evaluated. We decided to
retain low coverage variants in the list of candi-
dates to follow up only if detected in both affected
individuals, as the likelihood of this occurring by
chance is limited. Likewise, we decided to retain
variants that were not contributing to the partial
LOD in the linked region if co-segregating, giving
priority to the fact that variants were present in
both affected individuals and absent in the
intrafamilial control. This procedure identified 52
co-segregating variants in affected individuals
narrowing down to less than 1% of all variations
called within the linked regions (Fig. 1b and
Table S3).
Variants were annotated for scaled C-scores using
the unsupervised CADD score which prioritizes
functional, deleterious and pathogenic variants
across many functional categories. We found that
none of the co-segregating rare variants was pre-
sent in more than one family. However, two genes,
BCLAF1 and CHD5, were found to contain distinct
segregating variants in families 1, 36 and 385
(Fig. 1c).
Validation study: Sanger sequencing and variant segregation analysis
We performed Sanger sequencing to validate the
rare variants identified byWES and to confirm their
segregation in affected individuals and their
absence in the unaffected controls. Due to limited
DNAavailability for some of our families, we decided
to validate the 33 most promising variants (Fig. 1c,
Table 3 and Tables S3 and S4). Variant
S. N. Cox et al. Rare genetic variants in IgA nephropathy
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prioritization was performed in an unsupervised
way based principally on CADD score (28 variants,
score >5), gene expression in peripheral blood
leucocytes of IgAN patients [32–35] (JADE1 4:
g129783008t>a, UBE2G1 17:g4173166g>a and
LDLRAP1 1:g25894878c>g) and rare co-segregating
variants in the same gene in more than one family
(BCLAF1 6:g136579552a>g and BCLAF1 6:
g136579558a>g) (Table 3). Of the 33 variants, 28
(85%)wereconfirmedbydirectsequencing (Fig. 1d,e)
and the remaining five variants (USP6 17:
g5036210t>g, CAAP1 9:26841936c>a, USP22 17:
g20931986g>t, BCLAF16:g136579552andBCLAF1
6:g136579558) were not present. The two variants
predicted within the BCLAF1 gene were excluded
(see Figures S6 and S7). Four of the 28 variants
(Fig. 1d) were validated by Sanger sequencing
but also detected in the unaffected intrafamilial
control (B4GALT5 20:g48250578t>c, TOM1L2 17:
g17748047g>a, ERAL1 17:g27188606a>c and TG 8:
g133925492c>t).
On the whole, WES data were confirmed with
Sanger sequencing on 28 variants of which 24
were found to co-segregate with the IgAN affection
status. Most of these variants (63%, 15/24) fell
within untranslated or noncoding regulatory
regions of the genome.
We investigated whether all the 24 variants that
were segregating with biopsy-proven IgAN status
were also segregating with urinary abnormalities,
that are persistent microscopic haematuria and/or
mild proteinuria, in extended family members
included in WES (Figs 1f and 2, and Table S4). A
complete description of the variant segregation in
extended families can be found in the Supporting
information. Overall, all tested variants segregated
both with the IgAN status and with at least one
other family member with urinary abnormalities.
Moreover, in some families we detected putative
obligate carriers. These subjects were characterized
by normal urinalysis but carried all the mutations
(2397, 2162 and 2542); the presence of putative
obligate carriers within pedigrees is consistent with
the autosomal dominant mode of transmission of
this disease with incomplete penetrance for IgAN
[13–15, 36] and suggests that environmental trig-
gers together with genetic factors are needed for
disease onset [15, 37]. The identification of multiple
mutations in affected individuals suggests that
each one may cumulatively concur in determining
the disease.
Frequency evaluation: database query and TaqMan SNP genotyping
Next, we compared the frequencies of all 28 Sanger
sequencing-validated variants using two different
databases, the ExAC and the 1000 Genomes phase
3 databases; the former is the largest publicly
accessible exome-sequencing data set reporting
population frequency data of 60 706 unrelated
individuals and the latter contains genomewide
genotype data of 2504 individuals. We found that
amongst the 28 validated variants, 15 were private
and the remaining 13 were present in the databases
with a low frequency (MAF <0.003) (Table 3). Then,
we tested whether the frequencies of seven
randomly selected variants were higher in an inde-
pendent cohort of 240 IgAN patients compared with
113unrelatedHBDs (Fig. 1g). Furthermore, we also
tested all families who did not undergo WES, but
contributed to the linkage peaks from the original
GWLA study. The custom TaqMan SNP genotyping
assays were successfully designed for the following
variants: CAMK2D 4:g114374628t>a, THRA 17:
g38233146c>t, MIRLET7BHG 22:g46423973t>c,
JADE1 4:g129783008t>a, DFFA 1:g10527277g>c,
SETD5 3:g9515095c>a and UBE2G1 17:g4173166
g>a (Table S5). For each variant tested, we found
that it was only detected in the WES cohort in
which it was first discovered. No other IgAN
patients or HBDs carried the tested mutations.
These results suggest that the tested variants are
rare with a frequency of <0.002 in our IgAN
population.
Network analysis to identify rare family variants belonging to known
pathways
We investigated whether the 24 variants that co-
segregate with the IgAN affection status within 23
apparently unconnected genes were functionally
related and concurred to modulate a common
pathway. We tested this hypothesis in silico using
IPA Knowledge Base. This unsupervised analysis
identified a single network characterized by a high
connectivity score of 59 (Fig. 3a). Of 23 uploaded
genes, 22 were within this network (Fig. 3a, red
shaded genes). We found that AKT, CTNNB1,
NFKB, MYC and UBC were included as central
hubs of the network and all belonged to WNT/b-
catenin and PI3K/Akt signalling (Fig. 3a, cyan
coloured symbols). All these genes and pathways
are implicated in disease pathogenesis and are
aberrantly expressed both at gene and protein
levels in IgAN patients [35, 38–40]. In particular,
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when we overlaid our previously published expres-
sion data onto this network, we found that genes
and complexes with altered expression in IgAN
were also included in this network (ABHD2,
CTNNB1, CTNNb-LEF1, DFFA, HNRNPA1, JADE1,
KRTCAP2, LDLRAP1, let-7, MS4A4A, NR3C1,
SETD5, TCF4-CTNNb, TPRA1, Ube2-ubiquitin,
UBE2G1 and Ubiquitin (Fig. 3a, grey shaded sym-
bols) [32, 33, 35, 40, 41]. The representative
canonical pathways associated with the uploaded
genes are mainly involved in innate and adaptive
immunity (Fig. 3b).
Notably, the network included the gene encoding
the glucocorticoid receptor, also known as NR3C1,
which is the target of steroid therapy routinely
used in the treatment of IgAN. Corticosteroids are
able to lower the risk of kidney failure and reduce
proteinuria [2, 42, 43] (Fig. 3B). Furthermore, all
gene expression studies performed on IgAN
patients showed that the receptor NR3C1 signifi-
cantly influences various downstream molecules
aberrantly expressed in these patients [33–35]
(Fig. 3c–e: P = 9.46 9 106, P = 2.03 9 107 and
P = 1.88 9 104, respectively). The complete list of
potential drugs that act on this specific IgAN-
related network is shown in Table S6.
In conclusion, our results suggest that IgAN-
segregating variants interact with each other
generating a single network in which altered
immune-related pathways have a central role. This
network could highlight potential targets for a
targeted and personalized therapy.
Discussion
This is the first study designed to identify rare,
highly penetrant risk variants involved in IgAN
integrating two different genomewide approaches,
GWLA and WES. We identified 24 variants segre-
gating with IgAN patients and absent in their
intrafamilial controls. Furthermore, we confirmed
that these variants were either rare or private and
were characterized by a strong functional inter-
connectivity. In addition, these variants appeared
in a single network connected by central hubs
highly relevant to IgAN.
We first performed a GWLA using a finer SNP map
compared with previous linkage studies carried out
by microsatellites. The cumulative LOD scores
generated supported the previous linkage signals
on chromosome 6q22–23 [12] and on chromo-
somes 4q26–31 and 17q12–22 [13]. The identifica-
tion of additional linked loci is consistent with a
multiple susceptibility gene model for familial
IgAN, as suggested in previous linkage studies in
IgAN [12–14]. Furthermore, these linked loci were
once again distinct from the genomic areas identi-
fied by GWASs [5–9]. This discrepancy may be
ascribed to (i) differences in the genetic approach,
the former identified through a family-based
approach and the latter using population-based
approaches [44], and (ii) potential underlying dif-
ferences in the genetic determinants in familial and
sporadic IgAN [45].
GWLA was guidance for next-generation sequenc-
ing, and the results were used to provide an
informative, strictly selected subset of familial
cases enriched with putative highly penetrant
genetic risk variants, and genetically discordant
intrafamilial controls to be sequenced. This
approach was adopted to minimize the impact of
population stratification, as the quality control
methods developed for GWASs of common variants
should also be applied to rare variant studies [46].
Fig. 1 Overview of variant filtering and analysis strategy used to identify co-segregating variants in affected patients with
IgA nephropathy (IgAN). Two distinct algorithms from the Genome Analysis Toolkit (GATK) were used to call variants:
Haplotype Caller (HC) and Unified Genotyper (UG). These algorithms generated 150 913 and 137 045 variants,
respectively, in 24 exomes. Filtering was performed by removing (i) common variants defined by EUR.MAF >1%, (ii) low-
impact variants and (iii) variants that did not pass GATK filters. Linkage data were then included in the filtering step, and
only variants located within linked genomic intervals were further considered (a). We identified 52 variants that co-
segregated in affected individuals and were absent in the intrafamilial control generating a set of co-segregating variants
(b). These variants were visually inspected using the Integrated Genomics Viewer, and 33 were selected for Sanger
sequencing (c). Of these 33 selected variants, 28 were confirmed by Sanger sequencing. Four of these validated variants
were also detected in unaffected controls (B4GALT5, TOM1L2, ERAL1 and TG) (d). Thus, 24 variants segregated with the
IgAN status and were used for pathway analysis (e). The same 24 validated variants were used to determine whether they
were also co-segregating with urinary abnormalities (f). Finally, we tested the frequency of seven randomly selected
validated variants in an independent cohort of 240 IgAN patients and 113 unrelated healthy blood donors (g).
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Fig. 2 Rare variant segregation patterns in families with IgA nephropathy (IgAN). Heterozygous rare mutations that
segregated with the affection status were evaluated in extended family members. Squares and circles represent males and
females, respectively; arrows indicate probands, and slashes indicate deceased individuals. Filled and unfilled symbols
indicate individuals affected and unaffected by IgAN, respectively. Symbols with a dot indicate individuals with an
unknown phenotype (individuals without urinalysis or who had intermittent microscopic haematuria). Symbols with a
vertical line indicate individuals with documented urinary abnormalities (persistent microscopic haematuria and/or
proteinuria). The plus symbol indicates individuals who carry the corresponding heterozygous mutation, and the minus
symbol indicates those who carry the wild-type allele at this locus. The panels under each pedigree show representative
mutant electropherograms of the sequencing products obtained in the index patient (red arrow).
Fig. 3 Functional analysis of the network containing validated segregating variants. The network was algorithmically
constructed using Ingenuity PathwayAnalysis (IPA) software based on the functional andbiological connectivity of genes (a). The
network is graphically represented as nodes (genes) and edges (the biological relationship between genes). Red nodes represent
genes containing identified variants; others (empty nodes) are those that IPAautomatically includes because theyare biologically
linked to the studied genes based on evidence in the literature. This is the only network thatwasgenerated by thesoftware (score
59, n = 22 associated genes). UBC, AKT, CTNNB1 and NFKB are central nodes computed by the software (cyan colour). We
overlaidonto thisnetworkpreviouslypublishedexpressiondataobtained fromIgANpatientsandfoundthatdifferentlyexpressed
genes and complexes were included in this network (ABHD2, CTNNB1, CTNNb-LEF1, DFFA, HNRNPA1, JADE1, KRTCAP2,
LDLRAP1, let-7, MS4A4A, NR3C1, SETD5, TCF4-CTNNb, TPRA1, Ube2-ubiquitin, UBE2G1 and Ubiquitin; grey shaded
symbols). The most representative canonical pathways associated with the uploaded genes are mainly involved in innate and
adaptive immunity (b). The glucocorticoid receptor gene (NR3C1) is the target of steroid therapy (prednisone and methylpred-
nisolone) routinely used in IgAN treatment (a). The upstream regulator analysis identified NR3C1 as a transcriptional regulator
that explains the observed gene expression changes in differently expressed genes in peripheral blood cells (c, P = 9.469 106),
during the acute phase of the disease (d, P = 2.03 9 107) and in monocytes isolated from IgAN patients (e, P = 1.88 9 104).
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After applying filtering criteria and having visu-
ally inspected the genomic context, we identified
52 co-segregating variants. They were selected
due to their presence in both affected individuals
and absence in unaffected intrafamilial sequenc-
ing controls. Because the number of rare variants
in the human genome is very high [47], this
approach excluded co-segregating variants due to
the relatedness of the trios and rapidly narrowed
down the potentially causative and co-segregating
variants. The segregation analysis in our
extended families demonstrated that variants
segregated with the IgAN status and in individu-
als with persistent microscopic haematuria and/
or mild proteinuria. Furthermore, we also
detected putative obligate carriers in unaffected
family members. The presence of putative obli-
gate carriers within pedigrees is consistent with
the autosomal dominant mode of transmission of
this disease with incomplete penetrance for IgAN
[13–15, 36]. These obligate carriers provide evi-
dence that IgAN may be determined by multiple
genes and environmental factors that interact in
a complex network [15, 37]. A multihit model has
been postulated for IgAN [11, 48] in which other
environmental factors are needed for disease
onset, with genetic risk having recently been
shown to correlate strongly with variation in local
pathogens. In particular, helminth diversity con-
fers an increased risk in IgAN [8].
Then, we sought to evaluate whether the variants
identified in our WES cohort were also present in
other well-characterized IgAN patients and
unrelated HBDs, but none carried the tested
variants. The failure to identify a single rare
segregating variant in more than one family or
any of the rare variants in the other tested
familial or sporadic IgAN cases supports the
hypothesis that this complex and fairly common
disease may be ascribed not to a single gene or
variant but to a cumulative effect of rare variants
[49].
Finally, we focused on the 24 validated variants
within 23 genes that fulfilled the segregation crite-
ria in affected individuals and were not carried by
unaffected controls. The genes were interconnected
in a single functional network with AKT, CTNNB1,
NFKB, MYC and UBC as central nodes. These genes
appear to be biologically relevant because they are
key modulators of WNT/b-catenin and PI3K/Akt
pathways, which are altered in this disease [35,
39–41, 50].
The network included the glucocorticoid receptor
gene, NR3C1, which is the target of corticosteroid
therapy recommended by the KDIGO guidelines for
the treatment of IgAN [2, 43, 51]. We found that
NR3C1 significantly influences various down-
stream molecules aberrantly expressed in IgAN
patients and its modulation may contribute to the
beneficial effects of NR3C1 agonists in this disease
[2, 42, 43]. Due to the increased risk of adverse
events, the use of corticosteroids in IgAN has been
recently debated [52–55] and evokes the need for a
more targeted therapy. The analysis of other drug
targets included in this IgAN-related network could
be a starting point for future studies on personal-
ized therapies (Table S6).
Recently, a WES study has been performed on
individuals of Chinese Han ethnicity with familial
IgAN [56] and seven very common co-segregating
deleterious variants within five genes have been
identified. These variants were not present in our
filtered data set as we applied the stringent filtering
criteria of MAF <1%. We further checked our data
and found that there were no rare segregating
variants within these genes. This difference could
also be ascribed to the different ethnicity.
Our study has several limitations. First, because of
the limited availability of DNA, it is not possible to
validate all the segregating variants identified
bioinformatically. Nevertheless, we pursued 64%
of the variants (33 of 52) based mainly on the
systematic selection of their higher CADD score,
which is able to prioritize variants across func-
tional categories and effect sizes. Secondly, the
effect of each variation was not evaluated experi-
mentally. As an alternative approach, we overlaid
our previously validated experimental gene and
protein expression data onto the functional net-
work generated by IPA and found that statistically
significant differently expressed genes/complexes
in IgAN were included in the network. Further
studies are needed to understand whether these
variants can effectively disrupt normal function of
their relevant genes and whether such a disruption
may contribute to our phenotype of interest.
Despite these limitations, our study has several
strengths. First, our results suggest a multiple
susceptibility gene model for familial IgAN. Sec-
ondly, we have identified many rare segregating
variants that are involved in a common pathway
mostly with a role in innate and adaptive immu-
nity. Thirdly, the identified network contains genes
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and pathways previously demonstrated to be dys-
regulated in IgAN and drug targets that could be
exploited in the treatment of the disease.
IgAN is characterized by an altered innate immu-
nity [50] with a hyper-responsiveness of the IgA
immune system and an increased IgA-secreting
plasma cell number in both bone marrow and
tonsils [57, 58]. These cells show a reduced
susceptibility to Fas-mediated apoptosis with
marked expression of bcl-2 [59]. Furthermore,
WNT/b-catenin and PI3K/Akt pathways are hyper-
activated in peripheral blood mononuclear cells
with increased Akt phosphorylation, b-catenin and
NFkB nuclear translocation [35, 39] ultimately
leading to an enhanced cell proliferation rate. The
uncovering of 23 variant-containing genes, strictly
connected to these aberrant networks, may in part
explain the IgAN cell hyperactivated phenotype,
thus partly revealing the pathogenic mechanisms
of IgAN.
Conclusions
Together, our results support the novel hypothesis
that IgAN is caused by distinct rare segregating
variants, which may act within a specific IgAN
immune-related network. Our findings could be
used in future studies to test novel drug targets for
the treatment of this disease.
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